publication venue for
- Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. 2022
- Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status". 2022
- Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets. 2014
- Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases. 2022